Insurers Rejected 84% of Commercial and 65% of Medicare Claims for Oral Blood Cancer Drugs at First Submission
A peer-reviewed study found insurers first rejected 84% of commercial and 65% of Medicare claims for oral blood cancer drugs in 2022.
Medical Daily ·